MALAT1 and hepatocellular carcinoma: Subsequently, CRISPR/Cas9 technology was utilized to construct dCas9-MALAT1 plasmids for transfection into HBV/HBx-expressing HCC cells, ensuring stable and upregulated MALAT1 expression through the dCas9-SAM system (Fig. S3C) 23, 24.